Supplementary Figure S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer | Synapse
July 15, 2025
Supplementary Figure S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Key Points
MAIN FINDING: The combination of tifcemalimab and toripalimab was evaluated for effectiveness in advanced lung cancer.
KEY EVIDENCE: Kaplan-Meier estimates indicated differences in progression-free survival and overall survival rates.
APPROACH: A phase I/II study was conducted with assessment of immunotherapy responses in previously treated patients.
SIGNIFICANCE: This research provides insight into potential new treatments for advanced lung cancer patients.
Abstract
Supplementary Figure 3. Kaplan-Meier estimation of PFS and OS in SCLC with immunotherapy or not.